Neurocarrus

Name: Neurocarrus - AI Visibility Score
Creator: Engagemii
Published: 2026-06-25T23:11:31.718Z
License: https://creativecommons.org/licenses/by/4.0/

Unclaimed

AEO Score: 4/10

Crawled 1 times by AI engines

Claude

neurocarrus.com

X in f

What this score means

Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. Neurocarrus just got measured.

4/10 means Neurocarrus is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.

About Neurocarrus

Learn More Our crowd funding raise has started.

Key Topics

Neurocarrus uses the APOLLO targeting and delivery platform to treat neurons. The Apollo platform consists of three functionally independent components: i) Translocator- C2II, ii) Payload- C2I actin remodeler, and iii) Targeting- C1 receptor binder. The modularity of the Apollo platform allows for the design and development of engineered proteins in a combinatorial manner.

N-001 is a first-in-class therapeutic designed to treat the physiological symptoms of pain while avoiding systemic absorption and invasive surgical procedures. Pain is felt when sensory neurons transmit signals to the brain. Current treatments meant to disrupt pain signals from peripheral sensory neurons are not neuron-specific, and consequently suffer from a variety of off-target effects like addiction, muscle dysfunction, and destruction of surrounding tissues. As a superior alternative, Neurocarrus research and development aims to disrupt pain signals from sensory nerve cells via targeted delivery of engineered proteins. N-001 modifies the neuron's skeleton to block signalling. Unlike other existing FDA approved proteins in the marketplace, N-001 affects just sensory nerves, and leaves motor nerves untouched.

Neurocarrus’ non-addictive migraine preventive, NL-17, is a promising preclinical asset that will offer prolonged relief (>30 days) while enhancing patient adherence. By targeting sensory neurons, NL-17 controls migraine pain without addiction risk, systemic side effects, or sensory loss, avoiding the muscular dysfunction seen with opioids. Neurocarrus will shift the therapeutics paradigm from small molecules to a new class of engineered protein analgesics. Contribution to the NIH mission: Neurocarrus’ NL-17 will address the need for non-addictive, long-lasting preventive therapy for migraine with no side effects.

Neurocarrus’ non-addictive chronic pain therapeutic N-19a, is our third emerging preclinical asset, in this case developed for the treatment of chronic pain. While preserving the benefits of N-001, recent studies on N-19a offer tantalizing clues suggesting it may cure chronic pain. We are particularly excited to consider the possibility of a therapeutic that combines pain relief with healing the cause of pain.